GB9311281D0
(en)
*
|
1993-06-01 |
1993-07-21 |
Rhone Poulenc Rorer Ltd |
Novel composition of matter
|
US5698711A
(en)
|
1991-01-28 |
1997-12-16 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US5679696A
(en)
*
|
1992-07-28 |
1997-10-21 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
PL309257A1
(en)
*
|
1992-12-02 |
1995-10-02 |
Pfizer |
Pirocatechin doethers as selective inhibitors of ped iv
|
US5814651A
(en)
*
|
1992-12-02 |
1998-09-29 |
Pfizer Inc. |
Catechol diethers as selective PDEIV inhibitors
|
US5622977A
(en)
*
|
1992-12-23 |
1997-04-22 |
Celltech Therapeutics Limited |
Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
|
TW263495B
(zh)
*
|
1992-12-23 |
1995-11-21 |
Celltech Ltd |
|
GB9226830D0
(en)
*
|
1992-12-23 |
1993-02-17 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
DE69433997T2
(de)
*
|
1993-06-18 |
2005-01-27 |
Smithkline Beecham Corp. |
Verfahren zur Identifizierung eines PDE IV Hemmers
|
AU7267094A
(en)
|
1993-07-28 |
1995-02-28 |
Rhone-Poulenc Rorer Limited |
Compounds as pde iv and tnf inhibitors
|
US5665754A
(en)
*
|
1993-09-20 |
1997-09-09 |
Glaxo Wellcome Inc. |
Substituted pyrrolidines
|
CA2177375A1
(en)
*
|
1993-11-26 |
1995-06-01 |
Edward F. Kleinman |
3-aryl-2-isoxazolines as antiinflammatory agents
|
HUT76784A
(en)
*
|
1993-11-26 |
1997-11-28 |
Pfizer |
Antiinflammatory isoxazoline compounds and pharmaceutical compositions containing them
|
GB9326173D0
(en)
*
|
1993-12-22 |
1994-02-23 |
Celltech Ltd |
Chemical compounds and process
|
JP3806144B2
(ja)
*
|
1993-12-22 |
2006-08-09 |
セルテック セラピューティックス リミテッド |
三置換フェニル誘導体、その調製方法とホスホジエステラーゼ(iv型)阻害剤としてのその使用
|
CA2143143A1
(en)
*
|
1994-03-08 |
1995-09-09 |
Toshihiko Tanaka |
3-phenylpyrrolidine derivatives
|
EP0749307A1
(en)
*
|
1994-03-09 |
1996-12-27 |
Pfizer Inc. |
Isoxazoline compounds as 5-lipoxygenase inhibitors
|
ATE169009T1
(de)
*
|
1994-03-09 |
1998-08-15 |
Pfizer |
Isoxazoline verbindung zur hemmung tnf-freigabe
|
EP1380291A1
(en)
*
|
1994-04-21 |
2004-01-14 |
Schering Aktiengesellschaft |
PDE IV inhibitors for treating multiple sclerosis
|
PT758233E
(pt)
*
|
1994-04-21 |
2004-04-30 |
Schering Ag |
Inibidores pde iv para o tratamento da esclerose multipla
|
US5672622A
(en)
*
|
1994-04-21 |
1997-09-30 |
Berlex Laboratories, Inc. |
Treatment of multiple sclerosis
|
US6060501A
(en)
*
|
1994-06-02 |
2000-05-09 |
Schering Aktiengesellschaft |
Combined treatment of multiple sclerosis
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412573D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5591776A
(en)
*
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
US5563143A
(en)
*
|
1994-09-21 |
1996-10-08 |
Pfizer Inc. |
Catechol diether compounds as inhibitors of TNF release
|
US5665737B1
(en)
*
|
1994-10-12 |
1999-02-16 |
Euro Celtique Sa |
Substituted benzoxazoles
|
ATE247116T1
(de)
*
|
1994-12-13 |
2003-08-15 |
Euro Celtique Sa |
Arylthioxanthine
|
SK283821B6
(sk)
*
|
1995-02-10 |
2004-02-03 |
Schering Aktiengesellschaft |
Farmaceutické preparáty na inhibíciu tumornekrózafaktora
|
US6268373B1
(en)
|
1995-06-07 |
2001-07-31 |
Euro-Celtique S.A. |
Trisubstituted thioxanthines
|
US5658940A
(en)
*
|
1995-10-06 |
1997-08-19 |
Celgene Corporation |
Succinimide and maleimide cytokine inhibitors
|
DE19540475A1
(de)
*
|
1995-10-20 |
1997-04-24 |
Schering Ag |
Chirale Methylphenyloxazolidinone
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
ATE244713T1
(de)
*
|
1996-06-25 |
2003-07-15 |
Pfizer |
Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US5744473A
(en)
*
|
1996-09-16 |
1998-04-28 |
Euro-Celtique, S.A. |
PDE IV inhibitors: "bis-compounds"
|
GB9622363D0
(en)
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
WO1998028281A1
(en)
*
|
1996-12-23 |
1998-07-02 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
KR19980074060A
(ko)
*
|
1997-03-21 |
1998-11-05 |
김윤배 |
신규한 치환된 3,4-디알콕시페닐 유도체
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US6680336B2
(en)
|
1999-12-15 |
2004-01-20 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
US6372777B1
(en)
|
1999-12-23 |
2002-04-16 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
US6348602B1
(en)
*
|
1999-12-23 |
2002-02-19 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
FR2803593B1
(fr)
*
|
2000-01-06 |
2002-02-15 |
Sanofi Synthelabo |
Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
|
EP2258689A1
(en)
|
2000-03-16 |
2010-12-08 |
Biolipox AB |
Benzylated PDE4 inhibitors
|
IT1317049B1
(it)
*
|
2000-06-23 |
2003-05-26 |
Sigma Tau Ind Farmaceuti |
Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
|
WO2002081446A1
(en)
*
|
2001-04-06 |
2002-10-17 |
Daewoong Co., Ltd. |
3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
|
WO2002081447A1
(en)
*
|
2001-04-06 |
2002-10-17 |
Daewoong Pharmaceutical Co., Ltd. |
3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
|
FR2823748B1
(fr)
*
|
2001-04-20 |
2004-02-20 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
|
KR100874791B1
(ko)
|
2001-05-29 |
2008-12-18 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
Cdk-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
|
KR20090080573A
(ko)
*
|
2001-10-16 |
2009-07-24 |
메모리 파마슈티칼스 코포레이션 |
신경계 증후군의 치료를 위한 pde-4 억제제로서의 4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체
|
JP2004107323A
(ja)
*
|
2002-07-26 |
2004-04-08 |
Nippon Nohyaku Co Ltd |
新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法
|
AU2003252259A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Nihon Nohyaku Co., Ltd. |
Novel haloalkylsulfonanilide derivatives, herbicides and usage thereof
|
WO2004048334A1
(en)
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Phenyl substituted piperidine compounds for use as ppar activators
|
WO2004094375A2
(en)
*
|
2003-04-16 |
2004-11-04 |
Memory Pharmaceuticals Corporation |
4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
|
CA2522687A1
(en)
|
2003-04-18 |
2004-11-04 |
Memory Pharmaceuticals Corporation |
Pyrazole derivatives as phosphodiesterase 4 inhibitors
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
US20080085858A1
(en)
*
|
2004-10-13 |
2008-04-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Pharmaceutical Composition
|
US20070287689A1
(en)
*
|
2004-10-13 |
2007-12-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
|
US7432266B2
(en)
|
2004-10-15 |
2008-10-07 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
US7585882B2
(en)
|
2004-10-20 |
2009-09-08 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
US7517870B2
(en)
|
2004-12-03 |
2009-04-14 |
Fondazione Telethon |
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
PT2013211E
(pt)
|
2006-04-21 |
2012-06-21 |
Novartis Ag |
Derivados de purina para utilização como agonistas de receptores a2a de adenosina
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
US20100041662A1
(en)
|
2006-10-30 |
2010-02-18 |
Sandrine Ferrand |
Heterocyclic compounds as antiinflammatory agents
|
CA2673803A1
(en)
|
2007-01-10 |
2008-07-17 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
ATE499363T1
(de)
|
2007-05-07 |
2011-03-15 |
Novartis Ag |
Organische verbindungen
|
WO2009074575A2
(en)
|
2007-12-10 |
2009-06-18 |
Novartis Ag |
Organic compounds
|
ES2442930T3
(es)
|
2008-01-11 |
2014-02-14 |
Novartis Ag |
Pirimidinas como inhibidores de cinasas
|
BRPI0915018A2
(pt)
|
2008-06-10 |
2015-10-27 |
Novartis Ag |
compostos orgânicos
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
CN102573846B
(zh)
|
2009-08-17 |
2015-10-07 |
因特利凯公司 |
杂环化合物及其用途
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
US9102671B2
(en)
|
2011-02-25 |
2015-08-11 |
Novartis Ag |
Compounds and compositions as TRK inhibitors
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
US9174994B2
(en)
|
2011-11-23 |
2015-11-03 |
Intellikine, Llc |
Enhanced treatment regimens using mTor inhibitors
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
CA2945069A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
US10004732B2
(en)
|
2014-04-24 |
2018-06-26 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
MX2017001461A
(es)
|
2014-07-31 |
2017-05-11 |
Novartis Ag |
Terapia de combinacion.
|
JP2022537667A
(ja)
|
2019-06-10 |
2022-08-29 |
ノバルティス アーゲー |
Cf、copd、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
|
AU2020338971B2
(en)
|
2019-08-28 |
2023-11-23 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
CN114558002A
(zh)
*
|
2022-03-15 |
2022-05-31 |
四川轻化工大学 |
化合物在制备治疗肿瘤药物中的应用
|